Dashboard
Manage Tickers

SVRA


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jmp-securities-reiterates-market-outperform-on-savara-maintains-9-price-target
JMP Securities Reiterates Market Outperfor...
09/09/2024 14:22:07

JMP Securities analyst Jonathan Wolleben reiterates Savara (NASDAQ:SVRA) with a Market Outperform and maintains $9 price tar...

why-summit-therapeutics-shares-are-trading-higher-by-around-18-here-are-20-stocks-moving-premarket
Why Summit Therapeutics Shares Are Trading...
09/09/2024 10:08:36

reported-sunday-savara-unveils-phase-3-impala-2-trial-data-on-molgramostim-for-autoimmune-pulmonary-alveolar-proteinosis-at-ers-congress-2024
Reported Sunday, Savara Unveils Phase 3 IM...
09/09/2024 07:45:07

Mean Change From Baseline in Disease Severity Score (DSS) Showed Significant Improvement with Molgramostim Compared with Plac...

savara-announces-acceptance-of-abstract-for-poster-presentation-at-european-respiratory-society-congress-2024-in-vienna-will-present-results-from-impala-2-study-on-inhaled-molgramostim-for-autoimmune-pulmonary-alveolar-proteinosis-and-sponsor-an-industry-symposium
Savara Announces Acceptance Of Abstract Fo...
08/15/2024 12:23:18

hc-wainwright--co-reiterates-buy-on-savara-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Sava...
08/14/2024 18:15:11

HC Wainwright & Co. analyst Andrew Fein reiterates Savara (NASDAQ:SVRA) with a Buy and maintains $10 price target.

jmp-securities-maintains-market-outperform-on-savara-lowers-price-target-to-9
JMP Securities Maintains Market Outperform...
08/13/2024 11:51:38

JMP Securities analyst Jonathan Wolleben maintains Savara (NASDAQ:SVRA) with a Market Outperform and lowers the price target...

savara-q2-2024-adj-eps-012-misses-011-estimate
Savara Q2 2024 Adj EPS $(0.12) Misses $(0....
08/12/2024 20:06:07

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9...

savara-announces-pricing-of-100m-underwritten-offering-of-common-stock-of-26246720-shares-of-its-common-stock-at-a-price-of-381-per-share
Savara Announces Pricing Of $100M Underwri...
06/28/2024 12:50:43

Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the...

guggenheim-maintains-buy-on-savara-raises-price-target-to-10
Guggenheim Maintains Buy on Savara, Raises...
06/27/2024 17:29:58

Guggenheim analyst Daniel Krizay maintains Savara (NASDAQ:SVRA) with a Buy and raises the price target from $8 to $10.

hc-wainwright--co-maintains-buy-on-savara-raises-price-target-to-10
HC Wainwright & Co. Maintains Buy on Savar...
06/27/2024 10:11:55

HC Wainwright & Co. analyst Andrew Fein maintains Savara (NASDAQ:SVRA) with a Buy and raises the price target from $6 to...

oppenheimer-maintains-outperform-on-savara-raises-price-target-to-15
Oppenheimer Maintains Outperform on Savara...
06/26/2024 17:30:37

Oppenheimer analyst Francois Brisebois maintains Savara (NASDAQ:SVRA) with a Outperform and raises the price target from $11...

why-is-respiratory-disease-focused-savara-stock-trading-higher-on-wednesday
Why Is Respiratory Disease-Focused Savara ...
06/26/2024 13:36:38

Savara announces Phase 3 IMPALA-2 trial results for molgramostim in treating autoimmune pulmonary alveolar proteinosis. The inh...

savara-shares-are-trading-higher-after-the-company-announced-the-phase-3-impala-2-clinical-trial-met-its-primary-endpoints-and-multiple-scondary-endpoints
Savara shares are trading higher after the...
06/26/2024 11:42:11

savara-inc-announces-phase-3-trial-results-for-molgramostim-in-treating-rare-respiratory-disease
Savara Inc Announces Phase 3 Trial Results...
06/26/2024 10:33:16

Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today...

savaras-phase-3-impala-2-trial-of-molgramostim-met-statistical-significance-for-primary-endpoint-and-multiple-secondary-endpoints-in-autoimmune-pulmonary-alveolar-proteinosis
Savara's Phase 3 IMPALA-2 Trial Of Molgram...
06/26/2024 10:33:03

Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus ...

oppenheimer-maintains-outperform-on-savara-raises-price-target-to-11
Oppenheimer Maintains Outperform on Savara...
05/21/2024 11:59:29

Oppenheimer analyst Francois Brisebois maintains Savara (NASDAQ:SVRA) with a Outperform and raises the price target from $9....

reported-sunday-savara-and-trillium-health-presented-new-data-on-autoimmune-pulmonary-alveolar-proteinosis-at-ats-2024
Reported Sunday, Savara And Trillium Healt...
05/20/2024 05:46:10

Below are summaries of the posters presented: Poster Board 701: "Healthcare Burden of Pulmonary Alveolar Proteinosis" ...

evercore-isi-group-maintains-outperform-on-savara-lowers-price-target-to-7
Evercore ISI Group Maintains Outperform on...
05/16/2024 17:01:03

Evercore ISI Group maintains Savara (NASDAQ:SVRA) with a Outperform and lowers the price target from $10 to $7.

hc-wainwright--co-reiterates-buy-on-savara-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Sava...
05/13/2024 10:41:18

HC Wainwright & Co. analyst Andrew Fein reiterates Savara (NASDAQ:SVRA) with a Buy and maintains $6 price target.

savara-q1-2024-adj-eps-011-misses-010-estimate
Savara Q1 2024 Adj EPS $(0.11) Misses $(0....
05/09/2024 21:01:00

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 1...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION